NuCana Reports Fourth Quarter and Year-End 2019 Financial Results and Provides Business Update
March 10, 2020 16:02 ET
|
NuCana plc
First Patients Dosed in Global Phase III Biliary Tract Cancer Study (NuTide:121) with Potential for Accelerated Approval Filing Numerous Clinical Data Announcements Expected in 2020 Cash and Cash...
NuCana Reports Preliminary Data from Phase II Study of Single-Agent Acelarin (NUC-1031) in Patients with Platinum-Resistant Ovarian Cancer
March 10, 2020 16:01 ET
|
NuCana plc
Confirmed Complete Response and Two Partial Responses Achieved in Heavily Pre-treated Population Patients had Median of Five Prior Lines of Therapy EDINBURGH, United Kingdom, March 10, 2020 (GLOBE...
NuCana Receives Positive Opinion for Orphan Drug Designation in the European Union for Acelarin (NUC-1031) for the Treatment of Patients with Biliary Tract Cancer
March 04, 2020 07:00 ET
|
NuCana plc
EDINBURGH, United Kingdom, March 04, 2020 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced that the European Medicines Agency’s (EMA) Committee for Orphan Medicinal Products (COMP) has issued...
NuCana to Present at the Cowen and Company 40th Annual Health Care Conference
February 25, 2020 07:00 ET
|
NuCana plc
EDINBURGH, United Kingdom, Feb. 25, 2020 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced today that Hugh Griffith, Chief Executive Officer, and Don Munoz, Chief Financial Officer, will...
NuCana Announces First Patients Dosed in Both US and Europe in Phase III Study of Acelarin (NUC-1031) for the First-Line Treatment of Patients with Biliary Tract Cancer
January 27, 2020 07:00 ET
|
NuCana plc
Global NuTide:121 Study Is Enrolling up to 828 Patients and Comparing Acelarin plus Cisplatin to Gemcitabine plus Cisplatin NuTide:121 Trials-in-Progress Poster Presented at ASCO-GI SAN FRANCISCO,...
NuCana to Participate in the Piper Jaffray 31st Annual Healthcare Conference
November 26, 2019 07:00 ET
|
NuCana plc
EDINBURGH, United Kingdom, Nov. 26, 2019 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced today that Don Munoz, Chief Financial Officer, will host one-on-one meetings at the Piper Jaffray...
NuCana to Present at the Jefferies 2019 London Healthcare Conference
November 14, 2019 07:00 ET
|
NuCana plc
EDINBURGH, United Kingdom, Nov. 14, 2019 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced today that Hugh Griffith, Chief Executive Officer, and Don Munoz, Chief Financial Officer, will...
NuCana Reports Third Quarter 2019 Financial Results and Provides Business Update
November 13, 2019 16:01 ET
|
NuCana plc
Opens Phase III Global Biliary Tract Cancer Study (NuTide:121) with Potential for Accelerated Approval Filing Focusing Resources on Key Value-Driving Programs of Biliary Tract Cancer and Colorectal...
NuCana Presents Data at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
October 29, 2019 07:00 ET
|
NuCana plc
NUC-3373: Favorable Pharmacokinetic Profile Demonstrated NUC-7738: Multiple Anti-Cancer Mechanisms of Action Identified, including Inhibition of the mTOR Pathway BOSTON, Oct. 29, 2019 (GLOBE...
NuCana Announces FDA Clearance to Commence Phase III Study of Acelarin (NUC-1031) for the First-Line Treatment of Patients with Biliary Tract Cancer
October 25, 2019 07:00 ET
|
NuCana plc
Global NuTide:121 Study will Enroll up to 828 Patients and Compare Acelarin plus Cisplatin to Gemcitabine plus Cisplatin Primary Endpoints of Overall Survival and Objective Response Rate Three...